Hillhouse HHLR Increases NVIDIA Stake in Q2 as Biotech Exceeds Half of Portfolio
Nashnova编辑部
Hillhouse's secondary-market arm HHLR held $832 million across 35 U.S.-listed names at quarter-end, adding to Nvidia and optical-connectivity plays while biotech kept above 50% of the portfolio — a contrarian bet as several prominent Chinese managers slashed their Nvidia stakes.
What does this $832 million portfolio look like?
At Q2-end HHLR held 35 names with a total market value of roughly $832 million.
Top five positions: Legend Biotech, Futu Holdings, ArriVent, Marvell Technology, Vipshop. Legend Biotech rose to the No. 1 slot from a lower ranking in Q1.
Biotech accounted for over 50% of portfolio value. This means → HHLR's U.S. book is not a "tech fund" — it is a biotech-anchored portfolio that uses tech names as satellites.
AI infrastructure — what thesis is HHLR buying?
Q2 additions included Nvidia, Coherent, Corning, and Lumentum — semiconductor and optical-connectivity names, extending the Q1 direction.
Together with the existing Marvell stake, the portfolio now covers the three main AI-infrastructure links: compute chips, high-speed interconnect, and optical communications.
In plain terms = HHLR is not just betting on "who makes GPUs." It is wagering along the entire chain of how data gets processed, moved, and what materials carry it inside a data center.
Nvidia: others selling, HHLR buying — in the same quarter?
The divergence is stark. Gaoyi Asset cut over 70%, Greenwoods liquidated entirely, Duan Yongping's H&H sold 7.56 million shares (down 54.6%), and Oriental Harbour trimmed about 15.7%.
HHLR chose to add to Nvidia against the tide, standing on the opposite side of most prominent peers.
This reflects a market entering an "unraveling consensus" phase on AI: no one disputes the trend, but bulls and bears on compute-hardware valuations have sharply diverged.
Can you still hold Nvidia? — two logics collide
BULL
Capex cycle far from peak
AI compute leaders' market cap vs. next-year capex stays around 10× — the bubble is nowhere near dangerous.
Highest-certainty link
Compared with the application layer, compute demand is most predictable and fastest to monetize.
BEAR
Valuation pressure is showing
China's rapid model progress is making the market question the real return on massive capex.
Money is rotating
Cloud majors with platform ecosystems and stable cash flow are gaining valuation appeal at the expense of pure hardware plays.
In plain terms = both sides have a point — one watches whether money is still flowing in, the other watches whether the money flowing in can earn its way back. The divergence itself is the signal: AI investing is shifting from 'buy compute with eyes closed' to 'price each link on its own merits.'
What changed in the biotech anchor?
Two new names entered the book: Alamar Biosciences and Odyssey Therapeutics. Both were Hillhouse private-market investments that moved into the public portfolio after IPO.
This means → HHLR's biotech sleeve is not just public-market stock-picking — it is a natural extension of Hillhouse's private pipeline, creating a closed loop from venture to public holding.
BeiGene, a long-standing position, disappeared from the Q2 filing. However, a 13F reflects only securities reportable under U.S. rules — whether Hillhouse fully exited BeiGene cannot be concluded from this report alone.
What moved in the China-ADR sleeve?
HHLR added to Futu Holdings and Vipshop in Q2; both rank among the top five positions.
It adjusted holdings in Alibaba and other China ADRs; exact changes were not disclosed.
This reflects a selective rather than blanket approach to China ADRs: adding where earnings visibility is higher, not making a sector-wide bet.
Content is for reference only, not financial advice.